Anti-Human PD-L1 (Atezolizumab) [RG7446] — Fc Muted™
Anti-Human PD-L1 (Atezolizumab) [RG7446] — Fc Muted™
Product No.: LT1755
Product No.LT1755 Clone RG7446 Target PD-L1 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Programmed Death Ligand 1, B7-H1, PD-L1, CD274 Isotype Human IgG Applications FC , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Immunogen Unknown Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Atezolizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Atezolizumab. Atezolizumab recognizes an epitope on mouse PD-L1. This product is for research use only. Background PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction. Antigen Distribution PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. Ligand/Receptor PD-1 (PDCD1) Research Area Biosimilars . Cancer . Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Use of Atezolizumab Biosimilars as Calibration Standards in PK Bridging ELISACalibration and Reference Controls: In the development of pharmacokinetic (PK) bridging ELISA for measuring Atezolizumab concentrations, calibration standards are crucial for ensuring accurate quantification. These standards are typically derived from commercially sourced Atezolizumab (e.g., Tecentriq) or biosimilars that are calibrated against international standards, such as those from the National Institute of Biological Standards and Control (NIBSC) or the World Health Organization (WHO). Choice of Analytical Standard: For PK assays, it is recommended to use a single analytical standard to quantify both biosimilar and reference products. This approach minimizes variability and ensures that the assay is robust and reliable for bioequivalence studies. Biosimilars are often used as analytical standards if they are deemed bioanalytically equivalent through rigorous testing and validation. Validation Process: The validation of ELISA kits involves several steps:
Role in PK Bridging Studies: In PK bridging studies, these calibrated standards enable the accurate measurement of Atezolizumab concentrations in serum samples. This is essential for demonstrating bioequivalence between biosimilar and reference products, which involves comparing their pharmacokinetic profiles. To study tumor growth inhibition and characterize tumor-infiltrating lymphocytes (TILs) after administering a research-grade anti-PD-L1 antibody in vivo, researchers primarily use two types of models: syngeneic models and humanized models. Syngeneic ModelsSyngeneic models involve transplanting tumor cells from the same genetic background into mice. This setup allows for the study of tumor growth and immune interactions without the need for immunosuppression. Studies have used various syngeneic tumor models, such as MC38, Hepa1-6, CT-26, and EMT-6, to explore the effects of anti-PD-1 and anti-PD-L1 antibodies on tumor immunity and TILs. Humanized ModelsHumanized models, particularly those using non-obese diabetic scid gamma (NSG) mice engrafted with human T cells and other immune cells, have become instrumental in evaluating the efficacy of immunotherapies, including anti-PD-L1 antibodies. These models allow researchers to study the interaction between human immune cells and tumor cells in a more relevant setting, as they closely mimic the human immune environment. Both types of models are crucial for understanding how anti-PD-L1 antibodies affect tumor growth and modulate the immune response, particularly the infiltration and activity of TILs. Key Points of Each Model:
In terms of characterizing TILs, both models can provide insights into how anti-PD-L1 therapy enhances T cell infiltration and activity, although humanized models might offer more direct relevance to human tumor biology. Introduction to Atezolizumab and BiosimilarsAtezolizumab is an anti-PD-L1 monoclonal antibody used in cancer immunotherapy to enhance the immune system's ability to attack tumors. Biosimilars of atezolizumab are highly similar alternatives that are used primarily in research to study the drug's mechanisms and effects, offering cost-effectiveness and high fidelity to the original drug. Use of Biosimilars in Conjunction with Other Checkpoint InhibitorsResearchers use biosimilars of immune checkpoint inhibitors like atezolizumab in conjunction with other biosimilars (e.g., anti-CTLA-4 or anti-LAG-3) to study synergistic effects in complex immune-oncology models. This approach is based on the premise that targeting multiple immune checkpoints can overcome resistance and enhance therapeutic outcomes by complementing different mechanisms of action. Mechanisms and Strategies:
By combining biosimilars of different checkpoint inhibitors, researchers can explore novel therapeutic strategies to improve cancer treatment outcomes and better understand the complex interactions within the tumor microenvironment. Using Atezolizumab Biosimilar in Bridging ADA ELISAIn the context of immunogenicity testing, a biosimilar of Atezolizumab can be used as a capture or detection reagent in a bridging ADA ELISA to monitor a patient's immune response against the therapeutic drug. Here's how it might be utilized: Principle of Bridging ADA ELISA
Role of Atezolizumab Biosimilar
Advantages of Using a Biosimilar
Procedure for ADA Detection Using Atezolizumab Biosimilar
This method is highly sensitive, allowing for the detection of bivalent ADAs, which is crucial for assessing the patient's immune response to therapeutic drugs like Atezolizumab. However, the specificity of the assay can be influenced by components in human serum, necessitating the use of high-quality reagents and blocking solutions to ensure accurate results. References & Citations1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed 2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. 3. Freeman, G. et al. (2000) J. Exp. Med. 192:1027. Technical ProtocolsCertificate of Analysis |
Formats Available
